# Accreditation standards for stem cell transplant and CAR T-cell programmes (FACT-JACIE)

Source: https://onco.cc/protocols/fact-jacie-cellular-therapy-accreditation-standards/  
OnCo record `fact-jacie-cellular-therapy-accreditation-standards` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Hospitals that give stem cell transplants or CAR T-cell therapy can be inspected against international standards. To pass, a programme must show an experienced team, a minimum number of new patients a year, medicines available at any hour, access to intensive care or emergency services, a quality plan, and that it reviews its results. The standards describe a minimum, not best practice.

## Summary

The FACT-JACIE standards (haematopoietic cellular therapy, 9th edition version 9.1; immune effector cells, 3rd edition version 3.1; both effective 2 February 2026) are requirements for accreditation, not graded clinical recommendations. Each standard is a 'shall' (to be complied with at all times) or a 'should' (recommended, alternatives allowed, an explanation required for deviation). The notice in both documents states that they provide minimum guidelines and are not intended to establish best practices.

For a clinical programme the core requirements are: a designated team of a Clinical Program Director, a Quality Manager and at least one further attending physician, in place and treating for at least twelve months before first accreditation (B1.3); a director with at least two years as an attending physician managing transplant and cellular therapy patients (B3.1.1.1); a minimum number of new patients (Appendix I: at a single adult or paediatric site, 5 autologous recipients for an autologous-only programme, 10 allogeneic recipients for an allogeneic and autologous programme, and 3 immune effector cell recipients within a transplant programme, in the twelve months before accreditation and on average each year after; the immune effector cell standards, written for programmes that do not transplant, set 5 new patients at a single adult or paediatric site); access to intensive care or emergency services (B2.11); a pharmacy with 24-hour availability and prompt access to medicines for expected complications including cytokine release syndrome (B2.12); a written quality management plan (B4.2); complete data for the CIBMTR or EBMT registry forms (B9.2, a 'shall' in the transplant standards and a 'should' in the immune effector cell standards); and, for immune effector cells, regular assessment for cytokine release syndrome and neurological complications with a written escalation plan (B7.8).

On outcomes the transplant standards say 'should': one-year survival within or above the expected range against national or international data, with a corrective action plan required ('shall') if it is not met (B4.7.5). The immune effector cell standards have no survival standard; they require review of outcomes against criteria the programme sets (B4.7).

The two bodies differ on the cycle: three years for FACT-accredited programmes and four years for JACIE-certified programmes. Whether accreditation is required for a centre to give a licensed CAR T-cell product, or to be paid for a transplant, is decided by regulators, manufacturers and payers in each country and is not in the standards.

## Fields

- Kind: Protocol
- Last checked: 2026-11-17
- Also known as: FACT-JACIE standards; JACIE accreditation; FACT accreditation; accredited transplant centre; accredited CAR-T centre; cellular therapy programme accreditation; FACT-JACIE International Standards

## Connected records

- institutions: [Foundation for the Accreditation of Cellular Therapy](https://onco.cc/institutions/fact-cellular-therapy/)
- technologies: [Allogeneic stem cell transplantation](https://onco.cc/technologies/allogeneic-hsct/), [Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/), [Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered](https://onco.cc/technologies/rejuv-tx-long-term-follow-up-frameworks/)
- protocols: [Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids](https://onco.cc/protocols/crs-grading-and-management/), [GVHD prophylaxis after allogeneic stem cell transplant: choosing the regimen](https://onco.cc/protocols/allo-hct-gvhd-prophylaxis/), [ICANS after CAR T-cell therapy: ICE score, ASTCT grading, steroids and seizure management](https://onco.cc/protocols/icans-grading-and-management/), [Leukapheresis to collect T cells for CAR T-cell manufacture](https://onco.cc/protocols/car-t-apheresis/), [Referral and eligibility assessment for CAR T-cell therapy](https://onco.cc/protocols/car-t-referral-and-eligibility/)
- terms: [Apheresis (leukapheresis)](https://onco.cc/terms/apheresis/)

---
JSON: https://onco.cc/api/v1/entities/fact-jacie-cellular-therapy-accreditation-standards.json